ALS-008176 for respiratory syncytial virus infection

New England Journal of Medicine

Volumn 374, Issue 14, 2016, Pages 1391-1392

  De Vincenzo, John P ^a   McClure, Matthew W ^b   Fry, John ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b AliosBiopharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALS 008176; ANTIVIRUS AGENT; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; DEOXYCYTIDINE;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; HUMAN; IMMUNOLOGICAL MEMORY; LETTER; LOADING DRUG DOSE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRAL CLEARANCE; VIRUS LOAD; ANALOGS AND DERIVATIVES; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANTIVIRAL AGENTS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84963820657     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1516110     Document Type: Letter

References (2)

1. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31: 524-32.
2. Bagga B, Cehelsky JE, Vaishnaw A, et al. Effect of preexisting serum and mucosal antibody on experimental respiratory syncytial virus (RSV) challenge and infection of adults. J Infect Dis 2015; 212: 1719-25.